Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to

David B Stone1,2, Sephira G Ryman1,2, Alexandra P Hartman1,2

  • 1AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd., and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics.

Summary

Researchers identified specific white matter tracts using diffusion tensor imaging (DTI) that predict Alzheimer's Disease (AD) risk in mild cognitive impairment (MCI) patients. These brain imaging biomarkers show promise for early AD detection.